NCT03312283View on ClinicalTrials.gov

Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

April 2, 2019

Study Completion Date

April 2, 2019

Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG

lucentis

intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)

DRUG

QL1205

intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)

Trial Locations (1)

200000

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT03312283 - Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD | Biotech Hunter | Biotech Hunter